SML1611

Lafutidine

≥98% (HPLC)

• 同義詞: (Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetamide, 2-[(2-Furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]-acetamide
• 經驗公式（希爾表示法）: C₂₂H₂₉N₃O₄S
• CAS號碼: 118288-08-7
• 分子量：: 431.55
• MDL號碼: MFCD00867520
• 分類程式碼代碼: 12352200
• PubChem物質ID: 329825497
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: white to beige
• 溶解度: DMSO: 20 mg/mL, clear
• 儲存溫度: −20°C
• SMILES 字串: O=C(CS(CC1=CC=CO1)=O)NC/C=C\COC2=NC=CC(CN3CCCCC3)=C2
• InChI: 1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2-
• InChI 密鑰: KMZQAVXSMUKBPD-DJWKRKHSSA-N

描述

生化／生理作用

Lafutidine is a second generation H2 histamine receptor antagonist.

Lafutidine is a second generation H2 histamine receptor antagonist. Lafutidine has been used clinically to treat ulcers and gastro-esophageal reflux disease (GERD). Lafutidine has also been investigated as a treatment against peripheral neuropathy and for its protective stomach effects during cancer chemotherapies and long term ibuprofen use.

安全資訊

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H302
• 防範說明: P264 - P270 - P301 + P312 - P501
• 危險分類: Acute Tox. 4 Oral
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 1
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable